Dosing & Uses
Dosage Forms & Strengths
oral solution
- 0.05mg/mL
injectable solution
- 0.1mg/mL
- 0.25mg/mL
tablet
- 0.0625mg (Lanoxin only)
- 0.125mg
- 0.1875mg (Lanoxin only)
- 0.25mg
Atrial Fibrillation
Rapid digitalizing (loading-dose) regimen
- IV: 8-12 mcg/kg (0.008-0.012 mg/kg) total loading dose; administer 50% initially; then may cautiously give 1/4 the loading dose q6-8hr twice; perform careful assessment of clinical response and toxicity before each dose
- PO: 10-15 mcg/kg total loading dose; administer 50% initially; then may cautiously give 1/4 the loading dose q6-8hr twice; perform careful assessment of clinical response and toxicity before each dose
Maintenance
- PO: 3.4-5.1 mcg/kg/day or 0.125-0.5 mg/day PO; may increase dose every 2 weeks based on clinical response, serum drug levels, and toxicity
- IV/IM: 0.1-0.4 mg qDay; IM route not preferred due to severe injection site reaction
Heart Failure
As per ACCF/AHA guidelines, a loading dose to initiate digoxin therapy in patients with heart failure is not necessary
0.125-0.25 mg PO/IV qDay; higher doses including 0.375-0.5 mg/day rarely needed
Use lower end of dosing (0.125 mg/day) in patients with impaired renal function or low lean body mass
Dosing Modifications
Adjust maintenance dose by estimating CrCl and measuring serum levels
In heart failure, higher dosages have no additional benefit and may increase toxicity; decreased renal clearance may lead to increased toxicity
In geriatric patients, use lean body weight to calculate dose
Dosage Forms & Strengths
oral solution
- 0.05mg/mL
injectable solution
- 0.1mg/mL
- 0.25mg/mL
tablet
- 0.125mg
- 0.25mg
Heart Failure/Atrial Fibrillation
Use doses at the lower end of the spectrm when treating heart failure
Reduce dose by 20-25% when changing from oral formulation or IM to IV therapy
Premature neonate
- PO: 1st loading dose, 10-15 mcg/kg; 2nd and 3rd loading doses, 5-7.5 mcg/kg q6-8hr for 2 doses; maintenance: 5-7.5 mcg/kg/day divided q12hr
- IV/IM: 1st loading dose, 7.5-12.5 mcg/kg; 2nd and 3rd loading doses, 3.75-6.25 mcg/kg q6-8hr for 2 doses; maintenance: 4-6 mcg/kg/day divided q12hr
Full-term neonate
- PO: 1st loading dose, 12.5-17.5 mcg/kg; 2nd and 3rd loading doses, 6.25-8.75 mcg/kg q6-8hr for 2 doses; maintenance: 6-10 mcg/kg/day divided q12hr
- IV/IM: 1st loading dose, 10-15 mcg/kg; 2nd and 3rd loading doses, 5-7.5 mcg/kg q6-8hr for 2 doses; maintenance: 5-8 mcg/kg/day divided q12hr
Infants & children 1-24 months
- PO: 1st loading dose, 17.5-30 mcg/kg; 2nd and 3rd loading doses, 8.75-15 mcg/kg q6-8hr for 2 doses; maintenance: 10-15 mcg/kg/day divided q12hr
- IV/IM: 1st loading dose, 15-25 mcg/kg; 2nd and 3rd loading doses, 7.5-12.5 mcg/kg q6-8hr for 2 doses; maintenance: 7.5-12 mcg/kg/day divided q12hr
2-5 years
- PO: 1st loading dose, 15-20 mcg/kg; 2nd and 3rd loading doses, 8.75-10 mcg/kg q6-8hr for 2 doses; maintenance: 7.5-10 mcg/kg/day divided q12hr
- IV/IM: 1st loading dose, 12.5-17.5 mcg/kg; 2nd and 3rd loading doses, 6.25-8.75 mcg/kg q6-8hr for 2 doses; maintenance: 6-9 mcg/kg/day divided q12hr
5-10 years
- PO: 1st loading dose, 10-17.5 mcg/kg; 2nd and 3rd loading doses, 5-8.75 mcg/kg q6-8hr for 2 doses; maintenance: 5-10 mcg/kg/day divided q12hr
- IV/IM: 1st loading dose, 7.5-15 mcg/kg; 2nd and 3rd loading doses, 3.75-7.5 mcg/kg q6-8hr for 2 doses; maintenance: 4-8 mcg/kg/day divided q12hr
>10 years & <100 kg
Interactions
Interaction Checker
No Results

Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor

Adverse Effects
1-10%
Dizziness (4.9%)
Mental disturbances (4.1%)
Diarrhea (3.2%)
Headache (3.2%)
Nausea (3.2%)
Vomiting (1.6%)
Maculopapular rash (1.6%)
<1%
Anorexia
Cardiac dysrhythmia
Arrhythmia in children (consider a toxicity)
Frequency Not Defined
Visual disturbance (blurred or yellow vision)
Heart block (1°/2°/3°)
Asystole
Tachycardia
Warnings
Contraindications
Hypersensitivity
Ventricular fibrillation
Cautions
Use caution in chronic constrictive pericarditis, electrical cardioversion, severe bradycardia, severe heart failure, severe pulmonary disease, sick sinus syndrome, ventricular tachycardia, ventricular premature contractions, Wolff-Parkinson-White syndrome, electrolyte imbalance, hypothyroidism or hyperthyroidism, hypoxia, idiopathic hypertrophic subaortic stenosis, renal disease, concomitant diuretics
Not recommended in patients with acute myocardial infarction
Avoid in patients with myocarditis
Risk of advanced or complete heart block in patients with sinus node disease and AV block
Very narrow margin between effective therapeutic and toxic dosages: Therapeutic range, 0.5-2 ng/mL (target 0.5-1 ng/mL); toxic range, >2.5 ng/mL
Generally avoid if left ventricular systolic function preserved, although may be used for ventricular rate control in subgroup with chronic atrial fibrillation
Less effective in presence of hypokalemia or hypocalcemia; avoid hypercalcemia or hypomagnesemia, which may predispose to serious arrhythmias
Heart failure patients with preserved ventricular function, including acute cor pulmonale, amyloid heart disease, and constrictive pericarditis may be susceptible to digoxin toxicity
May cause false-positive ST-T changes during exercise testing
Do not switch between different PO forms or between brand and generic forms of digoxin; bioavailability varies
Serum levels drawn within 6-8 hours of dose will be falsely high because of prolonged distribution phase
Increased risk of estrogen-like effects in geriatric patients
Beriberi heart disease may not respond adequately if underlying thiamine deficiency not corrected
Atrial arrhythmias are difficult to treat if associated with hypermetabolic (hyperthyroidism) or hyperdynamic (hypoxia) states; treat underlying condition before initiating therapy
Avoid extravasation; ensure proper needle or catheter placement prior to and during administration
Monitor for proarrhythmic effects, especially with digoxin toxicity
Use caution in patients with acute myocardial infarction; may increase myocardial oxygen demand; during acute coronary syndrome, digoxin administered IV may be used to slow a rapid ventricular response and improve left ventricular function in the acute treatment of atrial fibrillation associated with severe LV function and heart failure or hemodynamic instability
Monitor serum concentration closely when used for rate control in patients with atrial fibrillation; serum concentration that is not properly controlled are associated with increased risk of mortality
Consider use of digoxin only in heart failure with reduced ejection fraction when symptoms remain despite guideline-directed medical therapy; withdrawal of digoxin in clinically stable patients with heart failure may lead to recurrence of heart failure symptoms
In hypertrophic cardiomyopathy, outflow obstruction may worsen due to positive inotropic effects of digoxin; avoid use unless used to control ventricular response with atrial fibrillation; in the absence of atrial fibrillation, digoxin is potentially harmful in the treatment of dyspnea in patients with hypertrophic cardiomyopathy
Avoid rapid IV administration in digitalized patients; may produce serious arrhythmias
Not necessary to routinely reduce or hold digoxin therapy prior to elective electrical cardioversion for atrial fibrillation; however, exclusion of digoxin toxicity is necessary prior to cardioversion; whithold digoxin and delay cardioversion until toxicity subsides if signs of digoxin excess exist
Pregnancy & Lactation
Pregnancy
Experience with digoxin in pregnant women over several decades, based on published retrospective clinical studies and case reports, has not led to the identification of a drug associated risk of major birth defects, miscarriage or adverse maternal and fetal outcomes
Untreated underlying maternal conditions (eg, heart failure, atrial fibrillation) during pregnancy pose a risk to the mother and fetus
Clinical considerations
- Pregnant women with heart failure are at increased risk for preterm birth; clinical classification of heart disease may worsen with pregnancy and lead to maternal or fetal death
- Pregnant women with atrial fibrillation are at an increased risk of delivering a low birth weight infant; atrial fibrillation may worsen with pregnancy and can lead to maternal or fetal death
Fetal/neonatal adverse reactions
- Digoxin has been shown to cross the placenta and is found in amniotic fluid
- Monitor neonates for signs and symptoms of digoxin toxicity, including vomiting, and cardiac arrhythmias
Dose adjustments during pregnancy and the postpartum period
- Digoxin requirements may increase during pregnancy and decrease in the postpartum period
- Monitor serum digoxin levels during pregnancy and the postpartum period
Labor or delivery
- Risk of arrhythmias may increase during labor and delivery
- Monitor patients continuously during labor and delivery
Lactation
The digoxin dose received through breastfeeding is up to 4% of the neonatal maintenance dosage, which is unlikely to be clinically relevant
There are no data on the effects of digoxin on the breastfed infant or the effects on milk production
Data
- Based on data from 2 lactation studies in a total of 13 breastfed infants, digoxin concentrations in breast milk ranged between 0.4-1 ng/mL following 0.25 mg/day dose in lactating women
- The amount of digoxin ingested daily by breastfed infants is ~0.03- 0.16 mcg/kg/day
- This translates to a relative infant dose of digoxin between 1-7% of the maternal weight-adjusted dose and about 0.2-4% of the neonatal maintenance dose
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Digoxin inhibits Na-K ATPase, which in turn causes increased availability of intracellular calcium in the myocardium and conduction system. Inotropy and automaticity are subsequently increased while conduction velocity is reduced. Therapy indirectly causes parasympathetic stimulation of autonomic nervous system, with consequent effects on the sino-atrial (SA) and atrioventricular (AV) nodes.
Digoxin reduces catecholamine reuptake at nerve terminals, rendering blood vessels more sensitive to endogenous or exogenous catecholamines. Increases baroreceptor sensitization, with consequent increased carotid sinus nerve activity and enhanced sympathetic withdrawal for any given increment in mean arterial pressure. At higher concentration, increases sympathetic outflow from the central nervous system (CNS) to both cardiac and peripheral sympathetic nerves. It also allows progressive efflux of intracellular potassium, with consequent increase in serum potassium levels.
Absorption
Bioavailability: 60-80 % (tablet); 70-85% (elixir)
Onset: 0.5-2 hr (PO) for initial effect and 2-6 hr for maximal effect; 5-30 min (IV) for initial effect and 1.5-4 hr for maximal effect
Duration: 3-4 days
Peak serum time: 1-3 hr (PO)
Distribution
Protein bound: 20-25%
Vd: 6-7 L/kg
Metabolism
Metabolized by liver
Metabolites: Digoxigenin bisdigitoxoside, digoxigenin monodigitoxoside (active)
Elimination
Half-life: 1-3 days
Excretion: Urine (57-80%), feces (9-13%; includes bile)
Administration
IV Compatibilities
Solution: D5/½NS with potassium chloride 20 mEq, D5W, LR, ½NS, NS
Additive: Bretylium, cimetidine, floxacillin, furosemide, lidocaine, ranitidine, verapamil
Syringe: Heparin, milrinone
Y-site: Bivalirudin, ciprofloxacin, cisatracurium, dexmedetomidine, diltiazem, famotidine, fenoldopam, gatifloxacin, heparin with hydrocortisone, Hextend, inamrinone, linezolid, meperidine, meropenem, midazolam, milrinone, morphine sulfate, potassium chloride, remifentanil, tacrolimus, vitamins B and C
IV Incompatibilities
Additive: Dobutamine
Syringe: Doxapram
Y-site: Amphotericin B cholesteryl sulfate, amiodarone, fluconazole, foscarnet, insulin (beef, pork, and Humulin R[?]), propofol
IV Preparation
Dilute with 4-fold or greater volume of SWI, D5W, or NS
IV Administration
Administer slowly by direct IV injection over minimum of 5 minutes (longer if given undiluted)
Do not administer if precipitate present
Drug is severe skin irritant when given IV/IM and may cause severe local skin reaction with possible sloughing
Storage
Store at controlled room temperature
Protect from light
Images
Patient Handout
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.